CEO Marshall Fordyce (Vera)
An ambitious GV-backed gene editing upstart re-emerges as a one-drug kidney company
In September 2019, Trucode Gene Repair launched, after two-plus years of early development, with $34 million from GV and Kleiner Perkins and ambitious
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
